ArticleAdvanced healthcare materials2026
Charting Morphotoxicity With Complementary Embryo Models.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Charting Morphotoxicity With Complementary Embryo Models.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Understanding developmental toxicity demands capturing the full spectrum of morphological diversity, or morphospace, that defines early human embryogenesis. Traditional toxicity testing methods, relying on animal models or simplified 2D cell cultures, inherently overlook the nuanced interplay between distinct developmental stages and cell lineages. Addressing this gap, we present an innovative high-throughput screening approach leveraging three complementary 3D stem cell-based embryo models: preimplantation stage blastoids, and early postimplantation stage epiblast-like (EPICs) and amnion-like clusters (AMNICs). Cultured in thermoformed microwell arrays, these models were systematically exposed to a library of 27 widely used compounds. Automated image-based analyses allowed for precise quantification of morphotoxic effects. Key findings include the identification of compounds such as ascorbic acid and valproic acid (VPA), which demonstrated distinct and opposing effects across the different embryo models, highlighting developmental stage-specific sensitivities. This integrative platform underscores the essential role of complementary embryo models to achieve robust and human-relevant developmental toxicity assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.